Sunil Sharma

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra et al. · New England Journal of Medicine · 2014 · 1.5K citations

Medicine, Oncology, Pharmacology +14

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1K citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 845 citations · Full text

Medicine, Oncology, Urology +17

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan et al. · The Lancet Oncology · 2016 · 470 citations · Full text

Medicine, Oncology, Pharmacology +9

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis J. Giles, Thomas Fischer, Jörge E. Cortes et al. · Clinical Cancer Research · 2006 · 314 citations

Medicine, Hematology, Pharmacology +17